Netrin-1 & Hepatocellular Carcinoma HCC

HCC Clinical Trial

— HCC-Net  

Official title:

Netrin-1 in Hepatocellular Carcinoma: Pathology, Preclinical Targeting, and Definition of Eligibility Criteria for Phase 1 Trials

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04766736
• Other study ID #: 69HCL19_0258
• Status: Recruiting
• Start date: July 1, 2019
• Est. completion date: December 31, 2022

Study information

• Verified date: February 2021
• Source: Hospices Civils de Lyon
• Contact: Fabien ZOULIM, Pr
• Phone: 4 26 10 93 55
• Email: fabien.zoulim[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 320
• Est. completion date: December 31, 2022
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• any patient suffering from HCC

• age >18

• informed consent provided

Exclusion Criteria:

• absence of informed consent

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• HCC

Intervention

Procedure:
• Quantification of netrin-1 signals by antibody-based approaches
Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.

Locations

Country	Name	City	State
France	Hepatogastroenterology service of the Croix-Rousse Hospital	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Netrin-1 expression patterns in HCC samples	Netrin-1 expression levels will be quantified by immunoblotting with ad hoc internal standards. Positivity threshold by IHC will be evaluated using ad hoc positive and negative control tissues. The densitometry approach will be used.	Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care.